Currently, control and prevention of respiratory illnesses is considered a health priority in most developed countries and managing the risk factors is necessary for improving the population’s health. Chronic obstructive pulmonary disease (COPD) is the 5th cause of death around the world and estimations have indicated that due to an increase in environmental pollution, this disease will become the 3rd cause of death in the future.
In previous studies, pulmonary infection with mycoplasma pneumoniae has been introduced as one of the causes for COPD exacerbation. Mycoplasma pneumoniae affects the upper and lower respiratory tract and its clinical manifestation is trachea-bronchitis accompanied by restlessness and dry coughs. The pathogenesis spectrum of this bacterium ranges from mild pharyngitis and trachea-bronchitis to acute pneumonia. Epidemiologic studies have shown that this bacterium is responsible for more than 20% of community acquired pneumonias.
In a cross-sectional study by the authors of the present letter, 66 patients over the age of 18 years who had presented to the emergency department of Imam Reza Hospital, Mashhad, Iran, with diagnosis of COPD exacerbation were evaluated. Sputum sample of the patients was obtained and sent to the laboratory for performing polymerase chain reaction (PCR). Mean age of the patients participating in this study was 67.28 ± 13.68 years (60.6% male). The result of PCR was positive in 6 patients out of the total of 66 patients (9.1%). The results of the present study showed that there was no correlation between age (p=0.18), sex (p=0.25), duration of being affected with COPD (p=0.20), consumption of antibiotics (p=0.35), smoking (p=0.62), opioid abuse (p=0.44), corticosteroid use (p=0.57), underlying illness (p=0.94) and health care—associated pneumonia (HCAP) (p=0.46) with mycoplasma infection. However, prevalence of leukocytosis (p=0.01) and myalgia (p=0.02) was significantly higher in the mycoplasma group.
Numerous studies have confirmed the presence of mycoplasma pneumoniae in exacerbation of COPD using serologic diagnosis. For instance, in a study by Lieberman et al. prevalence of mycoplasma pneumoniae in patients with COPD exacerbation was reported as 14.2% and in Meloni et al. study the prevalence of this infection was expressed to be 6.7%. These rates were reported between 5% and 14% in other studies.Thus, it seems that prevalence of mycoplasma is high in COPD exacerbation, but there is still no answer to the question if this infection results in exacerbation of COPD or not and there is controversy between the studies in this regard. Therefore, it is suggested to design case-control or cohort studies to find the answer to this question.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report. Respirology. 2017;22(3):575-601.
Rootmensen GN, van Keimpema AR, Looysen EE, van der Schaaf L, de Haan RJ, Jansen HM. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. Patient Education and Counseling. 2008;70(2):179-86.
Hobbs B, Zhou J, Castaldi P, Hawrylkiewicz I, Sliwinski P, Yim J, et al. Variants Tagging Serpina1 And Il27 Show Significant Association With COPD In A Meta-Analysis With Over 16,700 Subjects. Medico. 2016;8(9):10.
Muro S, Tabara Y, Matsumoto H, Setoh K, Kawaguchi T, Takahashi M, et al. Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study. Medicine. 2016;95(15):e3371.
Layani-Milon M-P, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, et al. Incidence of Upper Respiratory TractMycoplasma pneumoniae Infections among Outpatients in Rhône-Alpes, France, during Five Successive Winter Periods. Journal of clinical microbiology. 1999;37(6):1721-6.
Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clinical microbiology reviews. 2004;17(4):697-728.
Lieberman D, Lieberman D, Ben-Yaakov M, Shmarkov O, Gelfer Y, Varshavsky R, et al. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagnostic Microbiology and Infectious Disease. 2002;44(1):1-6.
Meloni F, Paschetto E, Mangiarotti P, Crepaldi M, Morosini M, Bulgheroni A, et al. Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community-acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations. Journal of chemotherapy. 2004;16(1):70-6.
Papaetis G, Anastasakou E, Tselou T, Sotiriou A, Rarra V, Roussou P, et al. Serological evidence of Mycoplasma pneumoniae infection in patients with acute exacerbation of COPD: analysis of 100 hospitalizations. Advances in medical sciences. 2010;55(2):235-41.
Diederen BM, Van der Valk P, Kluytmans JA, Peeters MF, Hendrix R. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal. 2007;30(2):240-4.
Varma-Basil M, Dwivedi SK, Kumar K, Pathak R, Rastogi R, Thukral S, et al. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. Journal of medical microbiology. 2009;58(3):322-6.
Varma-Basil M, Dwivedi SK, Kumar K, Pathak R, Rastogi R, Thukral SS, et al. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. J Med Microbiol. 2009;58(Pt 3):322-6.